Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna was established in the memory of the first President of Republic of India Dr. Rajendra Prasad (1963). The broad objective of the Institute is to undertake research on clinical, basic and applied aspects of Kala-Azar. RMRIMS is well equipped with clinical medicine with OPD and 50-bedded Indoor facility, and some of the modern equipment include fully automated clinical chemistry analyzer, semi-auto analyzer, flow cytometer, PCR, gel-documentation system, microarray, DNA sequencer, RT-PCR, 2D gel electrophoresis system, HPLC, FPLC, Cell–counter, Ion-selective analyzer etc. The institute is well recognized World Health Organization (WHO/TDR), Institute for One World Health, GlaxoSmithKline, DNDi, MSF, Bharat Serum and Vaccine Ltd. for clinical drug trials. RMRIMS has collaborations with DBT, European Commission, WHO/TDR etc. for advance basic and epidemiological research. The institute has been identified by WHO as reference centre for Leishmania parasite and Sera Bank; and serves as one of the WHO centres for RDT evaluation networking.

• 1. Number of publications (1985-2017): 418 2. Annual reports (06). 3. RMRIMS News Bulletin (06). 4. Hospital based surveillance for Kala-azar. 5. Phase IV trial of Miltefosine in the treatment of Visceral Leishmaniasis (WHO/TDR/ICMR/Zentaris). 6. Multicentric, Randomized, Controlled Clinical trial to assess the safety and efficacy of injectable Paromonycin in patients with Visceral Leishmaniasis (ICMR/WHO/TDR/OneWorld Health). 7. Clinico-pathological changes in Post Kala-azar Dermal Leishmaniasis (PKDL) lesions in relations to treatment and immune response. 8. Immuno-phenotyping of cellular infiltrates dermal tissue and peripheral blood from post Kala -azar dermal Leishmaniasis cases. 9. Reactive nitrogen and oxygen intermediate metabolism in patients with Visceral Leishmaniasis. 10. Antileishmanial bacterial metabolites from the sandfly (Phlebotomus argentipes) gut microbiota – isolation, purification, characterization and their therapeutic evaluation. 11. Removal of bacterial and yeast contamination from Leishmania promastigotes culture by Agar plating. 12. PCR based diagnosis of Visceral Leishmaniasis from suspected cases of Kala-azar in Bihar. 13. Biochemical and Molecular characterization of responsive and unresponsive Kala-azar isolated of Bihar. 14. Role of CD2 Antigen in T-cell signal Transduction pathway in visceral Leishmaniasis. 15. Leishmania antigen characterization for diagnosis of visceral Leishmaniasis. 16. Assessment of indigenous plant extracts for leishmanicidal and immunoprophylactic activities against Leishmania donovani for the control action plan against visceral Leishmaniasis in India. 17. Identification and characterization of sibling species of Phlebotomus argentipes relevant in transmission of Kala-azar. 18. Feasibility of application of remote sensing for prediction of Kala-azar epidemic in selected foci in Bihar. 19. Identification and characterisation of Leishmania donovani (promastigote) antigen of naturally and artificially infected Phlebotomus argentipes. 20. Evaluation of the impact of DDT and Malathion indoor residual spraying being used in malaria and Kala-azar control programmed on the disease prevalence. 21. Social and epidemiological aspects of visceral Leishmaniasis in Bihar, India. "Site preparation for vaccine trial" (A WHO-BHU-ICMR-RMRIMS Collaborative Project). 22. Study of grass root level functionaries of Kala-azar in Bihar. 23. Risk factors for Indian Kala-azar in endemic areas of Bihar. 24. Study of interaction of Kala-azar and HIV infection. 25. Hospital based sentinel surveillance for the sero-positive cases of HIV, HbB, HbC and VDRL in Bihar (India). 26. HIV screening at Voluntary Counseling and Testing Centre (VCTC) - under Bihar State AIDS control programme.